About The Column Group
The Column Group is a venture capital firm founded in 2007. It is primarily based out of San Francisco, United States. As of Oct 2026, The Column Group is an active investor, having invested in 51 companies, with 2 new investments in the last 12 months. It primarily invests in Series A round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and Enterprise Applications. Most recently it participated in the $***** Series C round of Hexagon Bio Overall, The Column Group portfolio has seen 13 IPOs and 11 acquisitions including key companies like Compass, Nurix Therapeutics and Johnson & Johnson. A lot of funds co-invest with The Column Group, with names like Foresite Capital sharing a substantial percentage of its portfolio. The Column Group has team of 22 people including 16 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Series B & 4 more
Portfolio IPOs
Portfolio Acquisitions
Portfolio Soonicorns
Deals in last 12 months
The Column Group's List of Top Investments
The Column Group has a portfolio of 51 companies. Their most notable investments are in RAPT and Plexium.Their portfolio spans across and United States. They have invested in Life Sciences, High Tech, Enterprise Applications and 6 other sectors, across stages such as Series A, Series B and 4 more. Here is the list of top investments by The Column Group:1. Compass
Real estate company that helps people buy, sell, and rent homes and apartments. The platform enables users to own a property by discovering properties to seal the deal. Users can browse listings and schedule viewings via the app. The apps are available for Android and iOS devices.
Key facts about Compass
- Founded Year: 2012
- Location: New York City (United States)
- Annual Revenue: $1B+ as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $1.51B
- Employee Count: 35,455 as on Sep 30, 2026
- Investors: Glynn Capital, Flying Cow Ventures and 42 Others
- Latest Funding Round: Post IPO, Jan 16, 2026, $*****
- Highlight: Public
Nurix provides the platform for controlling the body natural protein level and regulation. It offers its candidate ubiquitin E3 ligases which helps in treating a broad range of disease by the breakdown of protein in the cell. The many pipelines if the company includes, CBL -B, BTX which are at the preclinical and other prior stages of approval. It also focus in developing the drug for treatment of cancer, small molecule, immunoncology agents and others.
Key facts about Nurix Therapeutics
- Founded Year: 2009
- Location: San Francisco (United States)
- Annual Revenue: $50M - $100M as on Nov 30, 2025
- Stage: Public
- Total Funding till date: $173M
- Employee Count: 379 as on Sep 30, 2026
- Investors: Bain Capital Life Sciences, Foresite Capital and 9 Others
- Latest Funding Round: Series B, Mar 26, 2020, $*****
- Highlight: Public
Manufacturer, developer, and supplier of beauty care products, medical devices, and pharmaceutical products. The company working in medical devices are 3-D printing artificial joints personalized for each patient, while researchers in pharmaceuticals use AI to discover lifesaving drugs. It also pride on fostering healthy supplier relationships that are built on trust, transparency and unparalleled innovation, quality and reliability with an extended supply base comprising about 50,000 suppliers across our three business segments. In 2022, the company recorded annual revenues of $96.31B and a net profit of $12.72B.
Key facts about Johnson & Johnson
- Founded Year: 1886
- Location: New Brunswick (United States)
- Annual Revenue: $1B+ as on Dec 31, 2025
- Stage: Public
- Employee Count: 133,830 as on Sep 30, 2026
- Investors: Western Technology Investment, Alcor Fund and 17 Others
- Latest Funding Round: Conventional Debt, Feb 20, 2025, $*****
- Highlight: Public
Developer of small molecule drugs for the treatment of rare diseases. The company's lead product Ataluren is an orally administered small-molecule drug for the treatment of cystic fibrosis and Duchenne muscular dystrophy caused by nonsense mutations. Also, developing anticancer and antibacterial drugs.
Key facts about PTC Therapeutics
- Founded Year: 1998
- Location: South Plainfield (United States)
- Annual Revenue: $1B+ as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $248M
- Employee Count: 1,160 as on Sep 30, 2026
- Investors: Brookside Capital, BB Biotech and 29 Others
- Latest Funding Round: Post IPO, May 16, 2023, $*****
- Highlight: Public
5. Genentech
R&D company focused on manufacturing drugs for multiple therapeutic areas. Its products include oncology, immunology, neurology, metabolism, infectious diseases, and ophthalmology drugs. It also provides clinical trial information services.
Key facts about Genentech
- Founded Year: 1976
- Location: San Francisco (United States)
- Last Known Valuation: $*****
- Stage: Acquired
- Total Funding till date: $72.5M
- Employee Count: 18,197 as on Sep 30, 2026
- Investors: Ignite 500, The Column Group and 4 Others
- Latest Funding Round: Grant (prize money), Jan 30, 2025, $*****
- Highlight: Acquired
The Column Group's Year-on-Year Investment Trends
The Column Group has invested in 51 companies over the last 19 years, with an average of 3 new investments annually in the last 10 years. In 2025, it made 6 investments, while as of Oct 2026, it has made 6 investments in this year. Its most recent first time investment was in TriGemX Bio and most recent follow-on round was in Hexagon Bio.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 2 | 4 | 6 |
2025 | 1 | 5 | 6 |
2024 | 4 | 5 | 9 |
2023 | 1 | 4 | 5 |
2022 | 1 | 10 | 11 |
2021 | 2 | 7 | 9 |
2020 | 8 | 6 | 14 |
2019 | 3 | 7 | 10 |
2018 | 1 | 8 | 9 |
2017 | 3 | 3 | 6 |
The Column Group's Investments by Stage
The Column Group is primarily an Early Stage Investor investor majorly investing in Series A (35) rounds where average round size is $1.7B, Series B (7) rounds where average round size is $424M and Series C (2) rounds where average round size is $132M.Stage of entry | No. of Investments |
|---|---|
Series A | 35 |
Series B | 7 |
Series C | 2 |
Post IPO | 1 |
Seed | 1 |
Others | 1 |
Note: We have considered here, only first round of investments
The Column Group's Investments by Sector
The Column Group has a diverse portfolio, with companies operating in the Life Sciences, High Tech, Enterprise Applications, HealthTech and Healthcare. Notably, it has invested in 44 Enterprise (B2B) companies, 44 Tech companies, 8 Software companies and at least 4 companies focusing on Consumer (B2C).Sector | No. of Investments |
|---|---|
Life Sciences | 45 |
High Tech | 7 |
Enterprise Applications | 6 |
HealthTech | 5 |
Healthcare | 1 |
Others | 2 |
Note: We have considered here, only first round of investments
The Column Group's Investments by Geography
The Column Group has made most investments in United States (47).The Column Group's recent investments
The Column Group has made 6 investments in 2026 so far. Hexagon Bio and TriGemX Bio are the latest among them.Here are the most recent investments by The Column Group:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Oct 26, 2026 | United States | Series C | 6827 | [+3] | |
Oct 01, 2026 | United States | Series C | 9359 | [+1] | |
Sep 16, 2026 | United States | Series E | 7699 | [+3] | |
Aug 12, 2026 | United States | Series B | 8612 | [+6] | |
Jun 22, 2026 | United States | Series B | 9576 | [+2] |
IPOs and Publicly Listed companies in The Column Group's Portfolio
13 of The Column Group's portfolio companies have become public. Eikon got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Feb 2026 at marketcap of $908M and Sagimet Biosciences got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ) at marketcap of $330M.Here are The Column Group's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Feb 05, 2026 | May 05, 2021 | Series A | 7034 | |
Jul 14, 2023 | May 22, 2007 | Series A | 3007 | |
Aug 13, 2021 | Feb 15, 2017 | Series A | 5787 | |
Jul 30, 2021 | Dec 06, 2016 | Series A | 4218 | |
Apr 01, 2021 | - | - | 6427 |
Acquired companies in The Column Group's Portfolio
11 companies from The Column Group's portfolio have been acquired. The most recent acquisition was Neurona Therapeutics in Apr 2026 by UCB for $*****.Here are The Column Group's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Apr 21, 2026 | Dec 28, 2016 | Series A | 7069 | |
Jan 20, 2026 | May 04, 2016 | Series B | 9006 | |
Apr 23, 2024 | May 09, 2018 | Series A | 4078 | |
Dec 04, 2023 | Apr 07, 2010 | Seed | 3992 | |
Jun 02, 2021 | Apr 29, 2008 | Series A | 7768 |
Team profile of The Column Group
The Column Group has a team of 22 members including 16 Partners, 3 Venture Partners and 2 Principals located in United States. The Column Group's team sits on the board of 2 companies.Here is a list of top team members in The Column Group:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | San Francisco | - | ||
Partner | San Francisco | |||
Partner | San Francisco | - | ||
Partner | Los Altos | - | ||
Partner | San Francisco | - | ||
Partner | Stanford | - | ||
Partner | San Francisco | - | ||
Partner | Hayward | - | ||
Partner | New York City | - | ||
Partner | New York City | - | ||
Partner | United States | - |
Co-investors of The Column Group
Over the past 19 years, 290 investors have co-invested in The Column Group's portfolio companies. This includes funds and angels.
- Invested before The Column Group: Third Rock Ventures, HHS and 35 others have invested in rounds before The Column Group. There are 3 companies where Third Rock Ventures has invested before The Column Group and 3 companies where HHS has invested before The Column Group.
- Top Co-investors of The Column Group: 69 investors entered a company along with The Column Group. These include investors like Foresite Capital (5 companies).
- Invested after The Column Group: A total of 184 investors have invested in The Column Group's portfolio after their investments. Top Investors include Casdin Capital (9 companies), RA Capital Management (8 companies) and Euclidean Capital (6 companies).
Recent News related to The Column Group
•
TriGemX Bio Raises $94M in FundingFinSMEs•Oct 01, 2026•TCG Crossover, Viking Global Investors, The Column Group
•
Circle Pharma Announces $92.5 Million Series E Financing to Advance First-in-class Cyclin D1 Program into Clinical DevelopmentThe Joplin Globe•Sep 16, 2026•Circle Pharma, The Column Group
•
InduPro Announces $77 Million Series B Financing and Dosing of First Patient in Phase 1 Oncology Studyhttps://www.timesargus.com/•Aug 12, 2026•InduPro, Lilly, The Column Group, Sanofi and 5 others
•
Nura Bio Secures $74M Series B to Advance ALS Drugcitybiz•Jun 23, 2026•NURA, Euclidean, Sanofi Ventures, Samsara BioCapital and 1 other
•
•
Atavistik Bio Raises $120M in Series B FinancingFinSMEs•Dec 21, 2025•Nextech Invest, Lux Capital, Atavistik, Regeneron Ventures and 7 others
•
Nilo Therapeutics Launches with $101M Series A Funding and Appoints Kim Seth as CEOOct 09, 2025•The Column Group, DCVC, Lux Capital, Nilo Therapeutics and 2 others
•
Neurona raises $102m to advance cell therapy for drug-resistant epilepsyPharmaceutical Technology•Apr 03, 2025•Neurona Therapeutics, Fidelity Investments, The Column Group, Soleus Capital and 1 other
•
Surrozen’s $175 Million Oversubscribed Private PlacementGlobal Legal Chronicle•Apr 02, 2025•Surrozen, Gunderson Dettmer, The Column Group
•
Eikon Therapeutics Secures $350.7 Million Series D to Advance Clinical-Stage Programs and Future Pipelineintelligence360•Mar 14, 2025•Eikon, Lux Capital, Alexandria, AME Cloud Ventures and 6 others
